This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Perusing the Phase 3 topline results from study 501 evaluating Lumateperone in patients with major depressive disorder.

Ticker(s): ITCI

Who's the expert?

Institution: Private Practice

  • Board-certified psychiatrist in private practice at the Center for Anxiety and Depression.
  • Currently manages ~150 patients with major depressive disorder.
  • Previously served on active duty as a psychiatrist with the United States Navy.

Interview Goal
to discuss the current standard of care and the potential of Lumateperone as an adjunctive therapy in patients with major depressive disorder.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.